EPCAM and cancer: In monolayer culture, the CD24−/EpCAM+ cancer stem cell subpopulation was less than 1% (0.16±0.09%), and the subpopulation was not significantly changed by CDDO-Im treatment (0.18±0.04%) (Fig. 3A).